NO20070531L - TRPV1-agonister, formuleringer inneholdende dem og anvendelser derav - Google Patents

TRPV1-agonister, formuleringer inneholdende dem og anvendelser derav

Info

Publication number
NO20070531L
NO20070531L NO20070531A NO20070531A NO20070531L NO 20070531 L NO20070531 L NO 20070531L NO 20070531 A NO20070531 A NO 20070531A NO 20070531 A NO20070531 A NO 20070531A NO 20070531 L NO20070531 L NO 20070531L
Authority
NO
Norway
Prior art keywords
sub
applications
formulations containing
trpv1 agonists
hydrogen
Prior art date
Application number
NO20070531A
Other languages
English (en)
Other versions
NO338341B1 (no
Inventor
Paolo Morazzoni
Gabriele Fontana
Antonella Riva
Giovanni Appendino
Vincenzo Di Marzo
Original Assignee
Indena Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Indena Spa filed Critical Indena Spa
Publication of NO20070531L publication Critical patent/NO20070531L/no
Publication of NO338341B1 publication Critical patent/NO338341B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and unsaturated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/42—Separation; Purification; Stabilisation; Use of additives
    • C07C303/44—Separation; Purification
    • C07C303/46—Separation; Purification from by-products of refining mineral oils with sulfuric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/38—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D303/46—Compounds containing oxirane rings with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals by amide or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forbindelsene med generell formel (I). hvori. X representerer to hydrogenatomer, en Tt-binding, oksygen eller metylen;. R2 er et C-C-aryl, eller arylalkylresidu;. R3 er hydrogen, 2-hydroksyetyl eller 2-aminoetyl er nyttige for behandlingen av patologier mediert av vanilloidreseptorer type I.
NO20070531A 2004-07-30 2007-01-29 TRPV1-agonister, formuleringer inneholdende dem og anvendelser derav NO338341B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT001566A ITMI20041566A1 (it) 2004-07-30 2004-07-30 "trpv1 agonisti, formulazioni che li contengono e loro usi"
PCT/EP2005/007292 WO2006010445A1 (en) 2004-07-30 2005-07-06 Trpv1 agonists, formulations containing them and uses thereof

Publications (2)

Publication Number Publication Date
NO20070531L true NO20070531L (no) 2007-04-30
NO338341B1 NO338341B1 (no) 2016-08-08

Family

ID=34979120

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20070531A NO338341B1 (no) 2004-07-30 2007-01-29 TRPV1-agonister, formuleringer inneholdende dem og anvendelser derav

Country Status (19)

Country Link
US (1) US7429673B2 (no)
EP (1) EP1773757B1 (no)
JP (1) JP4819810B2 (no)
KR (1) KR101206571B1 (no)
CN (1) CN101006047B (no)
AT (1) ATE524433T1 (no)
AU (1) AU2005266684B2 (no)
CA (1) CA2575341C (no)
DK (1) DK1773757T3 (no)
ES (1) ES2370029T3 (no)
HK (1) HK1105947A1 (no)
IL (1) IL181024A (no)
IT (1) ITMI20041566A1 (no)
NO (1) NO338341B1 (no)
PL (1) PL1773757T3 (no)
PT (1) PT1773757E (no)
RU (1) RU2379282C2 (no)
SI (1) SI1773757T1 (no)
WO (1) WO2006010445A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
EP2224929B1 (en) 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
KR101034299B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Ｔｒｐｖ３ 활성 조절 약물 및 이의 활용
KR101034300B1 (ko) * 2008-12-02 2011-05-16 고려대학교 산학협력단 Ｔｒｐｖ３ 활성 억제 약물 및 이의 활용
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102725401A (zh) 2009-07-10 2012-10-10 哈佛大学校长及研究员协会 作为抗炎药的永久带电荷的钠和钙通道阻断剂
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
EP2531510B1 (en) 2010-02-01 2014-07-23 Novartis AG Pyrazolo[5,1b]oxazole derivatives as crf-1 receptor antagonists
ES2527849T3 (es) 2010-02-02 2015-01-30 Novartis Ag Derivados de ciclohexilamida como antagonistas del receptor de CRF
WO2011130414A1 (en) 2010-04-14 2011-10-20 Altria Client Services Inc. Preformed smokeless tobacco product
PT2629610T (pt) 2010-07-27 2017-11-24 Flex Pharma Inc Métodos e composições para prevenção e alívio de cãibras musculares e para recuperação de irritabilidade e fadiga neuromuscular após exercício
US10799548B2 (en) 2013-03-15 2020-10-13 Altria Client Services Llc Modifying taste and sensory irritation of smokeless tobacco and non-tobacco products
JP6833811B2 (ja) 2015-08-03 2021-02-24 プレジデント アンド フェローズ オブ ハーバード カレッジ 荷電イオンチャネル遮断薬及び使用方法
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
CA3129089A1 (en) 2019-03-11 2020-09-17 Bridget Mccarthy Cole Ester substituted ion channel blockers and methods for use
US10828287B2 (en) 2019-03-11 2020-11-10 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
JP2022527690A (ja) 2019-03-11 2022-06-03 ノシオン セラピューティクス，インコーポレイテッド 荷電したイオンチャンネル遮断薬および使用方法
US10780083B1 (en) 2019-03-11 2020-09-22 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CN113811305A (zh) 2019-03-11 2021-12-17 诺西恩医疗公司 带电的离子通道阻滞剂及其使用方法
WO2021091585A1 (en) 2019-11-06 2021-05-14 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
US10933055B1 (en) 2019-11-06 2021-03-02 Nocion Therapeutics, Inc. Charged ion channel blockers and methods for use
CA3170070A1 (en) 2020-03-11 2021-09-16 Bridget Mccarthy Cole Charged ion channel blockers and methods for use
RU2755206C1 (ru) 2020-05-20 2021-09-14 Федеральное государственное бюджетное учреждение науки Тихоокеанский институт биоорганической химии им. Г.Б. Елякова Дальневосточного отделения Российской академии наук (ТИБОХ ДВО РАН) Средство пролонгированного анальгетического действия и лекарственный препарат на его основе

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493848A (en) 1983-07-14 1985-01-15 The Procter & Gamble Company Compositions and methods useful for producing analgesia
FR2619810B1 (fr) * 1987-09-02 1990-01-05 Hoechst France Nouveaux monomeres ethyleniques polyfonctionnels
IT1302264B1 (it) * 1998-09-24 2000-09-05 Innovet Italia Srl Derivati a struttura n-acil vanillinamidica in grado di attivare irecettori periferici dei cannabinoidi
JP2004182674A (ja) * 2002-12-05 2004-07-02 Kureha Chem Ind Co Ltd バニリル脂肪酸アミドを含む抗腫瘍医薬組成物

Also Published As

Publication number Publication date
CN101006047A (zh) 2007-07-25
ATE524433T1 (de) 2011-09-15
PL1773757T3 (pl) 2012-02-29
NO338341B1 (no) 2016-08-08
IL181024A (en) 2011-12-29
EP1773757A1 (en) 2007-04-18
ES2370029T3 (es) 2011-12-12
JP2008508202A (ja) 2008-03-21
DK1773757T3 (da) 2011-11-21
AU2005266684A1 (en) 2006-02-02
ITMI20041566A1 (it) 2004-10-30
RU2007103344A (ru) 2008-08-10
HK1105947A1 (en) 2008-02-29
SI1773757T1 (sl) 2011-12-30
CA2575341A1 (en) 2006-02-02
KR101206571B1 (ko) 2012-11-29
PT1773757E (pt) 2011-10-27
CA2575341C (en) 2014-09-23
AU2005266684B2 (en) 2012-05-10
CN101006047B (zh) 2010-08-11
KR20070039078A (ko) 2007-04-11
WO2006010445A1 (en) 2006-02-02
IL181024A0 (en) 2007-07-04
RU2379282C2 (ru) 2010-01-20
US20080132573A1 (en) 2008-06-05
JP4819810B2 (ja) 2011-11-24
EP1773757B1 (en) 2011-09-14
US7429673B2 (en) 2008-09-30

Similar Documents

Publication Publication Date Title
DK1773757T3 (da) TRPV1 agonister, formuleringer indeholdende dem og anvendelser deraf
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
IL185275A0 (en) N-sulphonylpyrrole derivatives and pharmaceutical compositions containing the same
TW200612920A (en) Novel imidazolidine derivatives
DK1899325T3 (da) Imidazolinon- og hydantoinderivater som hidtil ukendte hæmmere af histondeacetylase
UA84208C2 (en) Tetraazabenzo(e)azulene derivatives and analogs thereof
EA200701176A1 (ru) Новые соединения нафталина, способ их получения и фармацевтические композиции, содержащие их
ATE433447T1 (de) Pyrimiidinverbindungen
NO20092412L (no) Hydantoinderivater anvendes som MMP-inhibitorer
MA31763B1 (fr) Inhibiteurs de kinase de type polo
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
MX2007008308A (es) Derivados de n-(heteroaril)-1h-indol-2-carboxamidas y su utilizacion como ligandos del receptor vaniloide trpv1-.
MX2010000658A (es) Derivados de pirimidina 934.
MX2007007025A (es) Nuevos derivados de hidantoina como inhibidores de metaloproteinasa.
SE0302139D0 (sv) Novel compounds
SE0200919D0 (sv) Chemical compounds
HK1081194A1 (en) 6-amino-1h-indazole compounds as phosphodiesterase4 inhibitors, pharmaceutical compositions compris ing the same, and use thereof
SE0403085D0 (sv) Novel componds
RS20060051A (en) Nicotinamide derivatives useful as pde4 inhibitors
GB0512284D0 (en) Organic compounds
DK1899331T3 (da) Homomorpholinoxazolidnoner som antibakterielle midler
DE602004018811D1 (de) Pyrrolidinylharnstoffderivate als angiogeneseinhibitoren
GB0215392D0 (en) Chemical compounds
SE0403117D0 (sv) New compounds 1
MXPA06000988A (es) Derivados de nicotinamida utiles como inhibidores de pde4.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees